Provexis plc (PXS.L) Research

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.

Market snapshot

Symbol
PXS.L
Price
$1.09
Day change
+3.33%
Market cap
$25.5M
P/E ratio
-42.15x
52-week range
0.00618-1.55
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Abingdon Health Plc (ABDX.L)
  • Chill Brands Group PLC (CHLL.L)
  • Cambridge Cognition Holdings Plc (COG.L)
  • Fusion Antibodies plc (FAB.L)
  • Genflow Biosciences plc (GENF.L)
  • Inspiration Healthcare Group plc (IHC.L)
  • IXICO plc (IXI.L)
  • N4 Pharma Plc (N4P.L)

Open Provexis plc (PXS.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.